Comparative Analysis of Persistence to Treatment among Patients with Asthma or COPD Receiving AirFluSal Forspiro or Seretide Diskus Salmeterol/Fluticasone Propionate Combination Therapy Bruce G. Bender, PhD, Ramon A. Hernandez Vecino, PhD, Kevin McGrath, MSc, Spencer Jones, PhD The Journal of Allergy and Clinical Immunology: In Practice Volume 4, Issue 5, Pages 884-889 (September 2016) DOI: 10.1016/j.jaip.2016.07.006 Copyright © 2016 The Authors Terms and Conditions
Figure 1 Kaplan-Meier survival (persistence) curve. The survival probability estimates at 12 months were 0.229 (0.02 standard error) for AirFluSal Forspiro versus 0.105 (0.025 standard error) for Seretide Diskus. The Journal of Allergy and Clinical Immunology: In Practice 2016 4, 884-889DOI: (10.1016/j.jaip.2016.07.006) Copyright © 2016 The Authors Terms and Conditions